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Abstract
Aberrant activation of membrane receptors frequently occurs in human carcinomas. Detection of phosphorylated receptors
is commonly used as an indicator of receptor activation in formalin-fixed paraffin embedded (FFPE) tumor specimens. FFPE
is a standard method of specimen preparation used in the histological analysis of solid tumors. Due to variability in FFPE
preparations and the labile nature of protein phosphorylation, measurements of phospho-proteins are unreliable and create
ambiguities in clinical interpretation. Here, we describe an alternative, novel approach to measure receptor activation by
detecting and quantifying ligand-receptor complexes in FFPE specimens. We used hepatocyte growth factor (HGF)-c-MET as
our model ligand-receptor system. HGF is the only known ligand of the c-MET tyrosine kinase receptor and HGF binding
triggers c-MET phosphorylation. Novel antibody proximity-based assays were developed and used to detect and quantify
total c-MET, total HGF, and HGF-c-MET ligand-receptor interactions in FFPE cell line and tumor tissue. In glioma cells,
autocrine activation of c-MET by HGF-c-MET increased basal levels of c-MET phosphorylation at tyrosine (Tyr) 1003.
Furthermore, HGF-c-MET activation in glioma cell lines was verified by Surface Protein-Protein Interaction by Crosslinking
ELISA (SPPICE) assay in corresponding soluble cell lysates. Finally, we profiled levels of c-MET, HGF, and HGF-c-MET
complexes in FFPE specimens of human Non-Small Cell Lung Cancer (NSCLC), Gastric Cancer, Head and Neck Squamous
Cell, and Head and Neck Non-Squamous Cell carcinomas. This report describes a novel approach for the detection and
quantification of ligand-receptor interactions that can be widely applied to measure receptor activation in FFPE preclinical
models and archived FFPE human tissue specimens.
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Introduction
Arguably, the most significant opportunity to improve response
rates for targeted therapeutics in solid tumors resides in the ability
to accurately match patient specific molecular alterations to drugs
that antagonize those alterations. This is the goal of personalized
medicine for oncology. In that context, measuring receptor
activation signatures constitutes an integral part of an overall
diagnostic strategy aimed at identifying potentially responsive
patients, stratifying patients for clinical trials and monitoring
therapeutic responses to a given drug. Post-translational modifi-
cations such as phosphorylation either at the level of the receptor
or downstream proteins, are likely to be better indicators of signal
pathway activation and thus drug susceptibility, than mere
quantification of receptor levels. In a clinical setting, formalin-
fixation followed by paraffin embedding (FFPE) is the most
common format of tissue preservation used by pathologists. This
format maintains antigenicity and ensures excellent cellular
morphology for diagnosis and immunohistochemistry (IHC)
applications. However, detection of phosphoproteins in FFPE
specimens is not robust in clinical settings, especially in clinical
surgical tissue samples. One reason may be due to rapid
dephosphorylation during ischemic stress after surgery [1,2].
During ischemia, opportunistic phosphatases in the cell are
activated and dephosphorylate proteins. It has been shown that
when tissues are not fixed immediately the ability to detect
phosphoproteins is lost within 60 minutes after biopsy [1].
Consequently, there is an urgent need to develop alternative
methods to measure receptor activation. Although not all of the
intricate details are known, there are a series of key steps leading to
receptor activation and subsequent signaling of cell growth and
proliferation. These key steps, ligand-receptor binding, receptor
dimerization, and receptor transphosphorylation resulting in the
production of substrate and adaptor protein binding sites, can be
measured as potential indicators of receptor activation. One can
also measure total receptor expression by IHC or FISH, or total
ligand levels by either IHC or ELISA, however, these are not
direct indicators of receptor activation.
Receptor tyrosine kinases (RTK) play essential functions in
regulating important cellular processes [3]. Aberrant activation of
RTK’s resulting from either by mutation, gene amplification, or
overexpression is significantly associated with many human
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15932Figure 1. Antibody proximity VeraTag assay. A. Assay work-flow. B. Antibody proximity assay design for quantification of receptor and ligand-
receptor complex.
doi:10.1371/journal.pone.0015932.g001
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targets and a number of RTK-directed drugs have received
regulatory approval for treatment of human cancers. c-MET is a
disulfide-linked a/b heterodimeric cell surface tyrosine kinase
receptor. Hepatocyte growth factor (HGF; also known as scatter
factor) is the only known c-MET ligand [5]. Binding of HGF to c-
MET triggers c-MET receptor activation via autophosphorylation
of the cytoplasmic domain and recruitment of adaptor proteins
Figure 2. VeraTag FFPE c-MET quantification and correlation with Western blot, ELISA and IHC in cell lines. A. Quantification of c-MET
expression in FFPE preparations of H441, H226, H2170, MCF7, Ln18, U138, U118, Ln229, U87, and H661 FFPE cell lines using the VeraTag assay.
Background signals generated using an isotype control IgG (shown in inset) were subtracted from the c-MET assay signals. B. Western blot analysis of
c-MET expression in H441, H226, H2170, MCF7, Ln18, U138, U118, Ln229, and H661 cell lysates. b-actin levels in the blot serves as a loading control. C.
ELISA measurements of c-MET expression in H441, H226, H2170, MCF7, Ln18, U138, U118, Ln229, and H661 cell lysates. ND: Not detectable. D. IHC
detection of c-MET expression in FFPE preparations of H441, H226, MCF7, Ln18, U118, and H661 cell lines.
doi:10.1371/journal.pone.0015932.g002
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signaling via ligand dependent (both paracrine and autocrine)
and ligand independent mechanisms is well documented in several
human cancers [4,5] and multiple therapeutic agents targeting this
pathway are in clinical development [4–6]. c-MET phosphoryla-
tion has been reported in Non-Small Cell Lung (NSCLC)
carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC),
and other carcinomas [7–9]. Like most receptor kinases, improved
methods for reliable measurement of c-MET receptor activation
are needed.
In this report, we describe the development of assays to detect
and quantify ligand-receptor complexes as surrogate measure of
receptor activation. Using an antibody proximity-based technol-
ogy (VeraTag), we describe a novel approach for the detection and
quantification of the HGF-c-MET ligand-receptor complex in
FFPE specimens including cell lines and human carcinoma tissues.
To our knowledge, this is the first report describing detection and
quantification of ligand-receptor complexes in the FFPE format.
Additionally, we also describe the development of assays to detect
and quantify total c-MET and HGF levels in FFPE specimens.
Our approach demonstrates the potential of antibody proximity
assays to provide reliable measurements of aberrant receptor
activation in FFPE specimens.
Materials and Methods
H441, H226, A549, H2170, MCF7, H661, Ln229, U87MG,
Ln18, U138, U118, and H596 cell lines were obtained from
ATCC (American Type culture collection, Manassas, VA) and
maintained in DMEM/F12 (50:50) containing 10% fetal bovine
serum (Invitrogen, Carlsbad, CA), 1% penicillin-streptomycin,
2 mM L-Glutamine (CellGro, Manassas, VA). Antibodies used in
this study are as follows: Mouse anti-c-Met (clone 3D4)
(Invitrogen, Carlsbad, CA), Rabbit anti-c-Met (CVD13) (Invitro-
gen, Carlsbad, CA), Anti-c-MET (clone SP44) (Spring Biosciences,
Pleasanton, CA), Human HGF affinity chromatography purified
Anti-human HGF (R&D systems, Minneapolis, MN), Anti-human
HGF Ab-2 (clone SBF5) (Thermo Scientific, Fremont, CA),
Figure 3. Epitope mapping of c-MET antibodies by peptide scanning. A. Peptide ELISA. A series of 43 overlapping peptides, each 14–15
amino-acid residues in length, spanning the complete intracellular domain of c-MET (K955-S1370), were evaluated to map the binding epitope of c-
MET antibodies. Peptides were spotted on microtiter plates and ELISA assays were performed using standard protocols. The binding properties of
peptide 28 and 43 localized the binding sites of c-MET antibody 3D4 and c-MET antibodies CVD13 and SP44, respectively. The sequence of peptide
#28 and #43 are shown (inset). B. A schematic representing the c-MET receptor and binding sites for c-MET antibodies.
doi:10.1371/journal.pone.0015932.g003
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MN), Phospho c-Met (Tyr 1003) (13D11) (Cell signaling, Beverly,
MA), Phospho c-Met (Tyr1234/1235) (D26) (Cell signaling,
Beverly, MA), Phospho c-Met (Tyr1349) (Cell signaling, Beverly,
MA), Rabbit monoclonal (DA1E) IgG (Cell signaling, Beverly,
MA), Horseradish peroxidase (HRP) conjugated secondary
antibodies (Pierce Biotechnology, Rockford, IL). Frozen or
formalin-fixed paraffin embedded human tumor blocks were
obtained from Asterand (Detroit, MI). Head and Neck tumors
were macrodissected to remove non-tumor related content.
Human Non-Small Cell lung carcinoma and human Gastric
carcinoma tissues used in the study had greater than 70% tumor
content. Cell lines were fixed in 10% neutral buffered formalin for
1 h at 4uC (Sigma, St. Louis, MO) and formalin-fixed paraffin
embedded (FFPE) pellets were prepared by as described [10].
VeraTag reporter molecules were synthesized as described earlier
[US Patent 7,105,308]. VeraTag reporter and biotin conjugated
antibodies were prepared as before [10].
c-MET assay for formalin-fixed paraffin embedded (FFPE)
cell lines and human tumor tissues
Sections were deparaffinized/rehydrated in xylene (265
minutes), 100% ethanol (265 minutes), 70% ethanol (265
minutes), and deionized water (265 minutes). Antigen retrieval
was performed with DIVA decloaker antigen retrieval buffer
(Biocare medical, Concord, CA) in a decloaking chamber (Biocare
medical, Concord, CA). After retrieval, slides were cooled for 1 h
at room temperature, washed in deionized water, and blocked
with sample blocking buffer (10% goat serum, 1.5% BSA, 1x PBS)
for 1 h at room temperature. After removal of blocking buffer,
sections were incubated at 4uC overnight with fluorescein-reporter
conjugated and Biotin conjugated c-Met antibodies prepared in
blocking buffer. Anti-c-Met (CVD13) (Invitrogen, Carlsbad, CA)
was used for VeraTag Pro11 reporter conjugation; Anti-c-Met
(clone 3D4) (Invitrogen, Carlsbad, CA) was used for biotin
conjugation). Fluorescein-reporter reporter conjugated c-Met
antibody: 0.5 mg/ml; biotin conjugated c-Met antibody: 1 mg/
ml. Isotype controls were performed as above except primary
antibodies were replaced with the following antibodies: fluoresce-
in-reporter conjugated c-Met antibody (CVD13): 0.5 mg/ml;
Biotin conjugated IgG2a (1 mg/ml). Antibody mixture was
removed by aspiration, sections were washed sequentially with
buffer 1 (0.25% TX-100, 1x PBS) and buffer 2 (1x PBS). Samples
were incubated for 1 h at room temperature with streptavidin-
conjugated methylene blue (2.5 mg/ml) prepared in 1x PBS. Slides
were washed with buffer 1 (0.25% TX-100, 1x PBS) (165 minutes)
followed by 3 changes of deionized water. An illumination buffer
(IB) (0.002x PBS) containing fluorescein (0.003pmol/L) and two
CE internal markers was added on top of the section and samples
were illuminated at 4uC for 1 h with in-house LED array that
mediated photo-activated cleavage of fluorescein-reporter mole-
cules. After illumination, buffer containing released reporters was
collected, and run on a capillary gel electrophoresis system
(ABI3100) (Applied Biosystems) under 6 kv for 50 s injection
conditions for separation and detection of VeraTag reporters.
Quantification of VeraTag reporter peaks was done using
customized VeraTag quantitative software that normalized the
peak area to the internal standard fluorescein, resulting in relative
peak area (RPA) that is proportional to the concentration of the
detected analyte. Tumor section area was measured using image J
as described before [10]. The final value of VeraTag fluorescein-
reporter was calculated by normalizing with tumor area (TA) and
volume of the illumination buffer (IB) using formula RPA*IB/TA
as described [10–12].
HGF assay for FFPE cell lines and human tumor tissues
Antibody proximity assays were performed as described above
except anti-c-Met antibodies were replaced with anti-human HGF
antibodies. Following antibodies were used for the assay: Anti-
human HGF (R&D systems, Minneapolis, MN) was used for
VeraTag reporter conjugation, Anti-human HGF (clone SBF5)
(Thermo Scientific, Fremont, CA) was used for biotin conjugation.
Pro11 fluorescein-reporter conjugated Anti-human HGF anti-
body: 0.5 mg/ml; biotin conjugated Anti-human HGF antibody:
1 mg/ml. Isotype controls were performed as above except
primary antibodies were replaced with the following antibodies:
Pro11 fluorescein-reporter conjugated Anti-human HGF antibody
(0.5 mg/ml); Biotin conjugated IgG1 (1 mg/ml).
HGF/c-MET ligand-receptor assay for FFPE cell lines and
human tumor tissues
Sections were deparaffinized/rehydrated, antigen retrieved, and
blocked using a blocking buffer as described above. Samples were
incubated overnight at 4uC with a mixture of unlabeled c-MET
antibody (SP44) (1 mg/ml) and Pro11 fluorescein-reporter conju-
gated anti-human HGF antibody (0.5 mg/ml) prepared in blocking
buffer. Antibody mixture was removed by aspiration, sections were
washed sequentially with buffer 1 (0.25% TX-100, 1x PBS) and
buffer 2 (1x PBS). Samples were incubated with biotin conjugated
goat anti-rabbit antibody (1 mg/ml) for 1 h at room temperature.
After this step, samples were washed sequentially with buffer 1 and
2, incubated with nutravidin-methylene blue (0.5 mg/ml), and
illuminated as described above. Fluorescein-reporter peaks were
normalized with tumor area as described previously [10–12].
Isotype control assay was performed as above except primary
antibodies were replaced with the following antibodies: Rabbit
monoclonal (DA1E) IgG (1 mg/ml); Pro11 fluorescein-reporter
anti-human HGF antibody (0.5 mg/ml). Tumors exhibited signals
at least 2-fold greater than the isotype assay control were scored
positive for HGF/c-MET complexes.
Immunoprecipitation and Western blotting
Cells were seeded in tissue culture dishes and incubated at 37uC
until 60–70% confluence.
Cells were starved overnight in serum free medium and
stimulated with various doses of HGF (PeproTechUS, Rockey
Hill, NJ) at 37uC for 10 minutes. Cells were washed with cold PBS
and lysed in buffer L (50 mM Tris-HCl (pH 7.5), 1% TX-100,
150 mM NaCl, 50 mM b-glycerophosphonate, 50 mM NaF,
1m MN a 3VO4 and a cocktail of protease inhibitors (Roche)).
Figure 4. c-MET quantification using the VeraTag FFPE assay and correlation with Western blot, ELISA and IHC in human tumor
specimens. A. Quantification of c-MET in NSCLC specimens using the VeraTag FFPE proximity assay. Isotype IgG antibody signal (inset) was
subtracted from c-MET assay signals. B. Western blot analysis of c-MET in corresponding NSCLC tumor lysates. b-actin levels in the blot serves as a
loading control. Ci. ELISA determinations of c-MET levels in corresponding NSCLC tumor lysates. Cii. Correlation of c-MET measurements in NSCLC
specimens by proximity assay and ELISA. Di. c-MET detection in NSCLC by IHC. Dii. Correlation of c-MET measurements in NSCLC by FFPE VeraTag
proximity assay and IHC. Histologic score (H-score) = %IHC3
+63 + %IHC2
+62 + %IHC1
+61 + %IHC060 was calculated as described [10]. Spearmen r
and p values were calculated using graphpad prism software.
doi:10.1371/journal.pone.0015932.g004
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13,000 rpm at 4uC for 10 minutes, and clear supernatant was
collected. Human tumor tissue lysates were prepared by first
adding frozen tumors in liquid nitrogen and then grinding tumors
using a pestle. Following sufficient grinding and mixing, cold
buffer L was added, samples were incubated for 20 minutes,
centrifuged at 13000 rpm, and clear supernatant was collected.
Protein concentration was measured using bicinchoninic acid
reagent (Pierce Biotechnology, Rockford, IL). Total cell lysates
were run on SDS-PAGE and western blots were probed with
various antibodies. Primary antibodies used for probing immuno-
blot are as follows: Anti-c-Met (clone 3D4) (Invitrogen, Carlsbad,
CA), Anti-human HGF (clone SBF5) (Thermo Scientific, Fremont,
CA), anti-b actin (Clone AC-74) (Sigma, St Louis, MO).
Immunoprecipitations were carried out using standard procedures
and captured on protein A/G beads (Santa Cruz Biotechnology,
Santa Cruz, CA). We used 200 mg and 2 mg of total protein,
respectively, for cell line and tumor lysates. Primary antibodies
used for immunoprecipitation are as follows:
Anti-c-Met (clone 3D4) (Invitrogen, Carlsbad, CA), Anti-human
HGF (clone A10)
(Enzo Life Sciences, Plymouth meeting, PA)
Peptide ELISA
A series of 43 peptides that span the entire intracellular domain
of c-MET (K955-S1390) were custom ordered (Elim biopharma-
ceuticals, Hayward, CA). Each peptide was 14–15 amino acids
long and contained 5 amino-acid overlapping sequence with the
adjacent peptide. Peptides were absorbed on the ELISA plates
overnight at 4uC. Plates were blocked with 3% BSA in PBS
containing 0.05% Tween 20 (PBSTw). Following 2 PBSTw
washes, antibodies were added. Following 3 washes, bound
antibody was detected with Horseradish peroxidase labeled
secondary antibody.
c-MET and HGF ELISA
Total c-MET ELISA assay was performed as per manufactur-
er’s instructions using a kit (R&D systems, Minneapolis, MN).
Total HGF ELISA assay was performed as per manufacturer’s
instructions using a kit (RayBiotech, Norcross, GA).
Immunohistochemistry and H&E staining
Samples were deparaffinized/rehydrated and heat-retrieved as
described above. Sections were blocked with blocking buffer (10%
BSA, 1.5% BSA, 1 mg/ml human IgG, 1x PBS) for 1 h at room
temperature and then incubated with either anti-c-Met (CVD13)
(Invitrogen, Carlsbad, CA) (1:400 dilution) or Anti-human HGF
(clone SBF5) (Thermo Scientific, Fremont, CA) (1 mg/ml) for 1 h
at room temperature. Sections were washed sequentially with wash
buffer 1 (0.25% TX-100, 1x PBS) and wash buffer 2 (1x PBS) and
incubated with secondary antibodies (Vector labs, Burlingame,
CA). Visualization of the c-Met or HGF on the sections was done
using an immunoperoxidase system (Vector labs, Burlingame, CA)
as per manufacturer’s instructions. Histologic score (H-score) =
%IHC3
+63 + %IHC2
+62 + %IHC1
+61 + %IHC060 was
calculated as described [10]. H&E staining of the tissues were
performed using standard procedures. Cell micrographs were
taken using a digital image camera mounted on a leica
microscope.
Covalent cross-linking and Surface Protein-Protein
Interaction by Cross-linking ELISA (SPPICE)
Covalent cross-linking using sulfo-EGS (Pierce Biotechnology,
Rockford, IL) was done as described [13]. After cell lysis, extracted
proteins were collected, and immunoprecipitated with Anti-
human HGF antibody (clone A10) (Enzo Life Sciences, Plymouth
meeting, PA). Eluted proteins were separated on SDS-PAGE using
Tris-glycine Gels, transferred to nitrocellulose membrane, and
immunoblotted with anti c-MET antibody (CVD13) (Invitrogen,
Carlsbad, CA).
To detect and quantify complexes by SPPICE assay, cross-
linked proteins were extracted after cell lysis and added to 96 well
microtiter plate pre-coated with c-MET capture antibody (R&D
systems, Minneapolis, MN). After overnight incubation at 4uC,
liquid was removed, followed by 3 washes with wash buffer (0.05%
Tween-20, 1xPBS). A biotin conjugated Anti-human HGF
detection antibody (RayBiotech, Norcross, GA) was added,
followed by 3 washes with 1xPBS. Detection of the complexes
was performed by adding streptavidin labeled Horseradish
peroxidase (RayBiotech, Norcross, GA). Plates were developed
by adding substrate as per manufacturer’s instructions (R&D
systems, Minneapolis, MN). Isotype IgG control assay was
performed as above except extracted protein samples were added
to 96 well microplate pre-coated with mouse IgG antibody (Becton
Dickenson, Franklin lakes, NJ). OD450 was calculated by
subtracting isotype IgG background from the assay specific signals.
Results
Proximity-based assays for the detection and
quantification of ligand, receptor, and ligand- receptor
complexes
Proximity-based VeraTag assays are antibody-based detection
methods to quantify proteins and protein complexes. This
approach has been successfully applied to the measurement of
HER2 receptor activation by detecting and quantifying HER2
and HER2 dimer levels in clinical FFPE specimens and soluble cell
lysate formats [10–12,14–15].
A schematic of the FFPE assay work-flow is shown in Fig. 1A.
Briefly, after deparaffinization and antigen retrieval, tissue sections
are incubated with a mixture of fluorescein-reporter antibodies
plus biotin-conjugated antibodies that recognize one or more
target analytes. As a second step, a streptavidin (SA) conjugated
photosenstizer (methylene blue; MB) is added which binds to the
biotin-conjugated antibody. In a third step, the tissue section is
illuminated with red light (670 nm) which triggers the SA-MB
photosensitizer to convert dissolved O2 in the buffer to reactive
singlet oxygen (
1O2). This reactive state of the oxygen in turn
cleaves thioether bonds linking the fluorescein- reporter to
conjugated reporter antibodies that are bound in close proximity
to the biotin-conjugated antibodies. The proximal selectivity of the
1O2 induced thioether cleavage is approximately 30 nm to
Figure 5. VeraTag FFPE quantification of HGF and correlation with Western blot, ELISA and IHC in cell lines. A. VeraTag FFPE
quantification of HGF in unstimulated and HGF stimulated A549 cells. Isotype IgG control signals (inset) were subtracted from the HGF signals. Bi.
VeraTag quantification of HGF in Ln18, Ln229, U138, U118, and U87MG glioma cell lines. Isotype IgG control signals (inset) were subtracted from HGF
assay signals. ND: Not detectable. Bii. ELISA determinations of HGF in A549, Ln18, Ln229, U138, U118, and U87MG cell lysates. ND: Not detectable. Ci.
VeraTag FFPE quantification of HGF in HEK293/HGF (clone 1) and U138 glioma cell lines. Cii. IHC detection of HGF in HEK293/HGF stable clone (clone
1) and U138 glioma cells.
doi:10.1371/journal.pone.0015932.g005
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1O2 [10]. In a final step, cleaved
fluorescein reporters are collected from tissue sections, resolved by
capillary electrophoresis, and quantified using customized VeraTag
software.
Proximity assays can be configured to detect either receptor and
ligand expression or ligand-receptor protein complexes by the
appropriate selection of antibodies that target receptor and/or
ligand. In proximity assays, receptor or ligand is detected and
quantified by fluorescein-reporter and biotin-conjugated antibodies
targeting different epitopes on the same protein (Fig. 1B). Converse-
ly, to detect and quantify ligand-receptor complexes, the fluorescein-
reporter conjugated antibody targets the receptor while the biotin-
conjugated antibody targets the ligand (Fig. 1B) or vice versa.
Detection and quantification of c-MET receptor in FFPE
cell lines by antibody proximity assays
The expression of c-MET has been studied in many epithelial
and mesenchymal cancers. In general, high expression of c-MET
is associated with poorer prognosis. High c-MET expression in
glioblastoma, breast cancer, gastric cancer, and ovarian cancer is
associated with poor survival [16–18]. Despite the availability of
semi-quantitative IHC assays for c-MET detection in FFPE
tissues, a method that can quantify a continuous measurement of
c-MET expression in tissues has not been developed.
We have developed a proximity assay for quantification of total
c-MET expression in FFPE specimens. We procured multiple c-
MET antibodies and assessed the specificity of each antibody in
FFPE samples. For the initial assessment of antibody specificity, we
used the lung cancer cell lines H1680 and H522 that express high
and undetectable levels of c-MET, respectively. From these
analyses, the c-MET (CVD13) rabbit polyclonal antibody and c-
MET (clone 3D4) mouse monoclonal antibody were selected for
further assay optimization.
Proximity assays were performed on a panel of FFPE specimens
prepared Non-Small Cell Lung, Breast, and Glioma Cancer cell
lines, using c-MET antibody pairs
CVD13 and clone 3D4 that were conjugated with either
fluorescent reporters or biotin. Cell lines were selected based on
their variable levels of c-MET protein expression: H441 express
high levels of c-MET, H226 and H2170 express intermediate levels
[19,20], MCF7 cells express low, but detectable levels of c-MET
[21] and H661 do not express c-MET [20]. We also used Ln18,
U138, U118, and Ln229 glioma cell lines. Cell line pellets were
prepared as FFPE specimens and analyzed for c-MET levels
(Fig. 2A). The H441 cell line exhibited the highest signals while
H226, Ln18, U138, U118, Ln229, and H2170 exhibited interme-
diate signals and the lowest c-MET were measured in MCF7 and
H661 cells. Isotype control assays using antibody matched IgG
generated signals that were less than 10% of the c-MET specific
signals (Fig. 2A). Together, these data indicate that the dynamic
range of c-MET proximity assays extends over a 2 log10 range.
In order to correlate FFPE proximity assay data with other
independent biochemical methods, we prepared soluble cell lysates
from the same panel of cell lines and conducted Western blot and
ELISA analysis. FFPE proximity assay measurements (Fig. 2A)
were generally concordant with Western blot (Fig. 2B) and ELISA
(Fig. 2C) results. We also performed IHC on FFPE cell line pellets
and as expected the c-MET staining pattern was highest in H441
cells and intermediate to low in the H226 and MCF7 cells
(Fig. 2D). Taken together, the c-MET FFPE assay exhibited a
broad range of specificity and data was consistent with
independent assays including Western blot, ELISA and IHC.
To further characterize the c-MET antibodies used in our
proximity assay, we mapped their binding epitopes in an ELISA
assay using a panel of overlapping peptides spanning the
cytoplasmic domain of c-MET. This analysis indicated that the
c-MET (clone 3D4) monoclonal antibody binds the epitope
(
1227RDMYDKEYYSVHNKT
1241) in the C-terminus of c-MET,
while the c-MET (CVD13) rabbit polyclonal binds the epitope
(
1378DEVDTRPASFWETS
1391) at the extreme C-terminus
(Fig. 3A, 3B). We also characterized a c-MET (clone SP44) rabbit
monoclonal antibody in the c-MET FFPE assay. These data
indicate that this rabbit monoclonal antibody (clone SP44) has c-
MET specificity similar to the c-MET rabbit polyclonal (CVD13)
antibody (data not shown). Characterization of this c-MET (clone
SP44) antibody by epitope mapping analysis indicated that it binds
to the epitope (
1378DEVDTRPASFWETS
1391) at the extreme C-
terminus (Fig. 3A, 3B) similar to the c-MET (CVD13) rabbit
polyclonal antibody and this enabled us to use this monoclonal
antibody (clone SP44) as an alternative to the polyclonal c-MET
(CVD13) antibody.
Detection and quantification of c-MET receptor in human
tumors by antibody proximity assay
In order to characterize c-MET levels in human tumors, we
obtained 15 human Non-Small Cell Lung (NSCLC) cancer
specimens. Portions of each tumor were prepared as formalin-
fixed paraffin embedded slides and soluble cell lysates (excluding
sample NL2 and NL8 due to small tumor volumes). These
NSCLC tumor samples displayed a ,20-fold range of c-MET
levels while isotype matched controls generated less than 10% of
the c-MET specific signal (Fig. 4A). To compare our FFPE
measurements with independent biochemical methods, we ana-
lyzed soluble lysates from the same panel of tumors using Western
blot (Fig. 4B) and ELISA (Fig. 4Ci). Generally, c-MET FFPE
measurements were concordant with Western blot and ELISA
data. A two-tailed comparison of c-MET protein levels measured
in FFPE specimens by proximity assay and by ELISA in soluble
lysates was statistically significant (Spearmen r: 0.91; p,0.0001)
(Fig. 4Cii). We also evaluated c-MET levels by IHC staining
(Fig. 4Di) and the comparison of FFPE c-MET levels by IHC H-
score and the proximity assay correlated with statistical signif-
icance (Spearmen r: 0.89; p,0.0001) (Fig. 4Dii). Taken together,
our results demonstrate that the c-MET FFPE assay can detect
and quantify c-MET receptor levels in FFPE tumor specimens,
and these measurements correlate well with measurements
obtained by conventional methods.
Detection and quantification of hepatocyte growth
factor (HGF) in cell lines by antibody proximity assays
Several studies have shown an association of serum or tumor
associated HGF with the progression of various carcinomas
[22,23]. High levels of HGF in resected NSCLC are correlated
with poor survival [23]. Despite the clinical significance of HGF
overexpression, a quantitative assay that measures HGF in FFPE
specimens has not been reported. To address this unmet need, we
Figure 6. VeraTag FFPE quantification of HGF and correlation with Western blot, ELISA, and IHC in human tumor specimens. A.
VeraTag FFPE quantification of HGF in NSCLC tumors. Isotype IgG control signals (inset) were subtracted from HGF signals. B. Immunoprecipitation/
Western blot analysis of HGF in corresponding NSCLC tumor lysates. C. ELISA determinations of HGF in corresponding NSCLC specimens. D. IHC
detection in NSCLC specimens.
doi:10.1371/journal.pone.0015932.g006
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a quantitative assay that measures HGF expression levels in FFPE
tumor specimens. A large panel of HGF antibodies was screened
for specificity using a stable cell line (HEK293/HGF (clone 1) that
overexpress HGF and the HGF negative parental cell line (HEK
293). Using these cell lines, we identified a goat polyclonal anti-
human HGF antibody and a mouse monoclonal anti-human HGF
antibody (clone SBF5) that exhibited high specificity. The
proximity assay was then optimized in two antibody format using
A549 cells in the presence of increasing amounts of HGF (Fig. 5A).
In agreement with a previous report [24], unstimulated A549 cells
exhibited low HGF expression (Fig. 5A). HGF measurements
using isotype antibody matched controls were less than 5% of the
HGF specific assay signals (Fig. 5A).
Next, we quantified HGF in cell lines that exhibit autocrine
HGF/c-MET signaling. We assessed endogenous level of HGF in
FFPE pellets generated from a panel of glioma cell lines (Ln229,
Ln18, U138, U118, and U87MG cells). U138, U118, and
U87MG possess an HGF/c-MET autocrine loop and secrete
HGF in the culture medium [23]. U118, Ln18, and U87MG
exhibited ,12–40 fold higher levels of HGF than U138 cell line
(Fig. 5Bi), while Ln229 cells produced no detectable HGF signal.
These measurements correlated well with the HGF ELISA
measurements we obtained using the corresponding glioma cell
lysates (Fig. 5Bii) and are in agreement with previous reports on
endogenous HGF expression in HGF in U138 and U118 cells
[25].
The dynamic range of the HGF proximity assay was defined as
,3 log10 by comparing the assay signals of the HEK293/HGF cell
line against the U138 cell line (Fig. 5Ci) and this is consistent with
detection of HGF by IHC in corresponding cell lines (Fig. 5Cii).
Detection and quantification of hepatocyte growth
factor (HGF) in human tumors by antibody proximity
assays
We utilized the same NSCLC tumor panel that was used for the
evaluation of the c-MET proximity assay to evaluate the HGF
proximity assay (Fig. 6A). NL7 was the only sample that exhibited
high HGF expression levels in this panel. Isotype antibody controls
signals were consistently less than 20% of HGF antibody-specific
signals (Fig. 6A). To compare HGF proximity assay measurements
to independent biochemical methods, we performed Western blot
and ELISA assays on the corresponding tissue lysates. HGF was
immuno-precipitated from 2 mg of cellular protein and probed for
HGF by Western blot analysis. Consistent with the HGF
proximity assay, sample NL7 exhibited high levels of HGF
compared to the other samples (Fig. 6B). ELISA analysis of the
HGF levels in these samples was also consistent with both the
proximity assay and Western blot measurements (Fig. 6C).
Furthermore, the results of the HGF proximity assays, ELISA,
and Western blot were all concordant with IHC staining (Fig. 6D).
Detection and quantification of HGF/c-MET ligand-
receptor interaction in FFPE cell line pellets by antibody
proximity-based assay and correlation with c-MET
(pY1003) phosphorylation
We used anti c-MET and anti-HGF antibodies that worked well
in the c-MET and HGF assays to develop a quantitative assay for
detection of HGF/c-MET complexes in FFPE specimens. As
illustrated in Fig. 7Ai, the assay is performed by (a) incubation of
FFPE samples with a rabbit anti-MET antibody (clone SP44)
together with a human anti-HGF antibody that is conjugated to a
VeraTag reporter, (b) addition of biotin-conjugated goat anti-
rabbit antibody which binds to the rabbit anti-MET (clone SP44)
antibody, (c) addition of streptavidin-methylene blue, which serves
as photosensitizer, and (d) illumination of the sample, which
activates the photosensitizer and releases VeraTag reporters in
close proximity (see Fig. 1A). This secondary antibody format
enhances signal strength which in turn improves assay sensitivity
and reproducibility (Wallweber J, Unpublished data). A similar
format has been applied to the quantitative measurements of the
truncated form (p95) of the HER2 receptor in breast cancer [11].
To demonstrate the ability of our new assay to detect the HGF/c-
MET complex, we performed the assay on unstimulated and HGF
stimulated A549 cells. As illustrated in Fig. 7Aii, we observed
increases in the HGF/c-MET complex in the HGF stimulated
A549 cells which were proportional to the dosage of HGF. To
assess the extent of assay background resulting from non-specific
antibody binding, replicate samples (adjacent sections) were
incubated with the VeraTag labeled anti-HGF antibody and an
isotype (IgG DA1E) in place of the anti-MET antibody. In this
case, isotype control signals were less than 20% of the HGF/c-
MET complex specific signals (Fig. 7Aii (inset)). Additionally, we
could demonstrate a decrease in the HGF/c-MET complex signal
in HGF treated A549 cells when HGF was pre-incubated with an
HGF neutralizing antibody (clone 24612) (Fig. 7Aii). To rule out
that this decrease in HGF/c-MET signal was not due to assay
interference by neutralizing antibody binding, we verified that the
addition of a 10-fold excess of HGF neutralizing antibody did not
interfere with the assay (data not shown). Furthermore, we also
observed a corresponding decrease in c-MET phosphorylation
when HGF was pre-incubated with the HGF neutralizing
antibody (data not shown).
Next, we evaluated whether the FFPE assay could be used to
detect endogenous levels of HGF/c-MET complexes in glioma cell
lines that activate c-MET signaling through the autocrine
production of HGF [25]. As illustrated in Fig. 7B, the HGF/c-
MET complex was detected in the Ln18, U138, U118, and
U87MG cell lines but not in the Ln229 cells (Fig. 7B). This result is
consistent with the HGF and c-MET data we present in Fig. 2A
and Fig. 5Bi, respectively, i.e. Ln229 cells express intermediate
levels of c-MET but not endogenous HGF. Once again, we
verified that the signals from isotype control assays were less than
20% of the HGF/c-MET specific assay signals (Fig. 7B (inset)).
Furthermore, there was no significant difference in the HGF/c-
MET and isotype control signals for MCF7 and H661 cell lines
which express very low or no c-MET and do not express
endogenous HGF (Fig. 7B).
Next, we sought to correlate the presence of autocrine driven
HGF/c-MET complexes in glioma cells with a direct indicator of
c-MET activation. Upon ligand activation, c-MET is phosphor-
ylated, most notably at amino acid positions Y1003, Y1234/1235,
and Y1349. In addition, c-MET phosphorylation (pY1003) is a
marker of HER1 inhibitor (gefitinib) resistance in NSCLC patients
[26]. We measured c-MET pY1003 levels by immuno-precipita-
tion in lysates prepared from the Ln18, Ln229, U118, U138, and
U87MG glioma cell lines to compare with the HGF/c-MET levels
MET ligand receptor complexes in H661, MCF7, HGF stimulated MCF7, Ln18, Ln229, U138, U118, U87MG cell lines. C. Immunoprecipitation/Western
blot analysis of c-MET (Tyr1003) phosphorylation and c-MET in Ln18, Ln229, U138, U118, and U87 MG glioma cells. The H596 cell line with exon 14
(L964-D1010) deletion was included as a negative control for c-MET (Tyr1003) phosphorylation.
doi:10.1371/journal.pone.0015932.g007
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line containing a deletion in c-MET exon 14 that removes amino
acids L964 through D1010 [27] was used as a negative control for
our c-MET (pY1003) immuno-precipitation studies. As illustrated
in Fig. 7C, higher basal c-MET (pY1003) phosphorylation was
detected in Ln18 and U87MG cells relative to U138 and U118
cells. This observation is consistent with the detection of higher
levels of HGF/c-MET complex in Ln18 and U87MG cells relative
to U138 and U118 cells using the VeraTag FFPE assay format
(Fig. 7B). Interestingly, the Ln229 cell line that lack measurable
levels of the HGF/c-MET complex in the FFPE assay (Fig. 7B)
exhibited elevated levels of c-MET (pY1003) phosphoryaltion in
the lysate immunoprecipitation assay (Fig. 7C).
Detection of HGF/c-MET ligand-receptor complexes by
Surface Protein-Protein Interaction by Cross-linking ELISA
(SPPICE) assay
We developed a novel biochemical method for detection of the
HGF/c-MET complex to cross-validate the VeraTag HGF/c-
MET assay. Chemical cross-linking of proteins is commonly used
to demonstrate protein-protein interactions, therefore, we com-
bined chemical crosslinking with ELISA based detection to
develop Surface Protein-Protein Interaction by Cross-linking
ELISA (SPPICE). A schematic of the HGF/c-MET SPPICE
assay is depicted in Fig. 8A, and details of the assay are described
in Materials and Methods. Briefly, cell cultures expressing surface
c-MET receptors in the presence of either exogenous or
endogenous HGF are treated with a membrane impermeable
sulfo-EGS cross-linker. Soluble cross-linker proteins are subse-
quently extracted and the lysates are applied to 96 well microtiter
plates pre-coated with c-MET antibody. A biotinylated HGF
antibody is added and HGF/c-MET complexes are detected by
further addition of streptavidin-HRP and colorimetric substrate.
SPPICE was used to assess HGF/c-MET levels in unstimulated or
HGF stimulated A549 cells. We detected HGF dose-dependent
increases in the HGF/c-MET complex only when the cells were
treated with the sulfo-EGS cross-linker (Fig. 8Bi). In the absence of
the cross-linker treatment, the HGF/c-MET complex was not
detected in either unstimulated and HGF stimulated A549 cells.
The detection of HGF/c-MET ligand-receptor complexes by
conventional SDS-PAGE and Western blot analysis further
corroborated the SPPICE results (Fig. 8Bii). To assess endogenous
levels of HGF/c-MET ligand-receptor complexes in glioma cells,
we used SPPICE to characterize Ln18, Ln229, and U118 cell
lysates. Consistent with the proximity FFPE assay (Fig. 7C),
SPPICE detected HGF/c-MET complexes in Ln18 and U118
cells but not in Ln229 cells (Fig. 8C).
Profiling c-MET, HGF, and HGF/c-MET ligand-receptor
complexes in human NSCLC, Gastric, and Head and Neck
tumors by antibody proximity assays
We measured HGF/c-MET ligand-receptor complexes in the
same NSCLC carcinoma tumor panel that was used for individual
c-MET and HGF measurements. c-MET, HGF, and HGF/c-
MET levels were also measured in six gastric carcinomas and 33
Head and Neck (HN) carcinomas. The HN tumors included 17
squamous cell and 16 non-squamous cell carcinomas. Tumors
were rank ordered based on increasing HGF levels and
corresponding c-MET and HGF/c-MET complex measures are
represented as a heat map in Figs. 9A, B, C. The HGF/c-MET
complex was detected in 7 of 13 (54%) NSCLC specimens (NL1,
NL4, NL5, NL6, NL11, NL15), 3 of 6 (50%) gastric tumors (G2,
G3, G5), and 11of 33 (33%) HN tumors (HN1, HN5, HN7, HN8,
HN12, HN15, HN16, HN21, HN25, HN26, HN33). Within HN
group, HGF/c-MET was detected in 7 of 17 (40%) squamous cell
carcinomas (HN1, HN5, HN7, HN8, HN21, HN25, HN26), and
4 of 16 (25%) non-squamous cell carcinomas (HN12, HN15,
HN16, HN33). Tumors identified positive for HGF/c-MET
ligand-receptor complexes exhibited signals that were at least 2-
fold greater than the isotype assay control signals (data not shown).
A combined analysis of NSCLC, gastric, and HN tumor
measurements did not reveal significant correlations between
HGF/c-MET levels and c-MET expression (pearson r =0.1782;
p=0.2063) or HGF expression (r=-0.021; p=0.8794). It is
important to note that HGF/c-MET measurements were not
simply the products of the individual HGF and c-MET
measurements (pearson r=0.1164; p=0.4112). We also compared
our HGF/c-MET measurements in the proximity FFPE assay
with the levels of c-MET (pY1003), c-MET (pY1234/1235), and c-
MET (pY1349) phosphorylation detected in NSCLC and gastric
tumors. Due to the low abundance of phosphorylated c-MET
protein in tumor samples, c-MET was immunoprecipitated prior
to immuno-detection by Western blot (Fig. 9Di, ii). c-MET
(pY1003) phosphorylation was detected in 9 NSCLC tumor lysates
(NL1, NL2, NL3, NL4, NL5, NL6, NL8, NL14, and NL15) and
the HGF/c-MET was also detected in 5 of 6 corresponding FFPE
sections by proximity FFPE assay (NL1, NL4, NL5, NL6, and
NL15). Two tumors (NL2, NL8) were too small (,20mm
2) to run
in the FFPE format. c-MET (pY1003) phosphorylation was
detected in only two gastric tumor lysates (G2, G3) and these
same tumors were also positive for HGF/c-MET complexes by
proximity FFPE assay. In one gastric tumor lysate (G6), a slightly
higher molecular weight/slower migrating band that also reacted
with the c-MET (pY1003), however, at the present time, the
identity of this protein is uncertain (Fig. 9Dii). Our attempts to
detect c-MET (pY1234/1235) and c-MET (pY1349) phosphory-
lation in NSCLC and gastric tumors were unsuccessful (data not
shown) suggesting that phosphorylation at these sites might be
labile than c-MET (pY1003).
Discussion
The c-MET, HGF, and c-MET/HGF assays described in this
report are based on the release of antibody conjugated fluorescein
reporters by antibody conjugated molecular scissors that are
bound in close proximity. This technology has been used to
measure total HER2 receptor and HER2 homodimer levels in
breast tumor FFPE specimens [10,28] and several studies have
demonstrated the clinical utility of these measurements [11,12,28].
In this report, we used the HGF/c-MET ligand-receptor
interaction as a model for the development of a ligand-receptor
proximity assay as a method to measure receptor activation in
FFPE specimens.
We have generated assays to quantify the expression of c-MET,
HGF, and HGF/c-MET ligand-receptor complexes in FFPE cell
lines and human carcinomas and have cross-validated these
measurements using independent biochemical methods. The
expression of c-MET and HGF is associated with tumor
progression and a number of clinical studies have implicated the
followed by Western blotting with anti-c-MET antibodies (Bii). C. c-MET and endogenous HGF in glioma cells were cross-linked as described above
and SPPICE was used to measure HGF/c-MET complexes.
doi:10.1371/journal.pone.0015932.g008
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measurements [16,17,18,22,23]. Based on the AQUA
TM platform
commercially available c-MET antibodies demonstrate lot to lot
variation that result in poor reproducibility of c-MET measure-
ments [29]. We screened a large panel of commercially available c-
MET and HGF antibodies and optimized a pair of antibodies for
use in proximity assays. The use of two antibodies that bind in
close proximity undoubtedly contribute to the high specificity of
detection of the assays described here.
To develop a HGF/c-MET ligand-receptor assay, we utilized the
c-MET and HGF antibodies that worked well in our FFPE assays.
We also incorporated a secondary antibody detection format that
enhances assay signal strength and reproducibility [11]. In cell lines
and tumors that were positive for HGF/c-MET, signals were more
than 2 fold higher than the isotype IgG control signals. In addition,
detection of endogenous levels of HGF/c-MET in glioma cells was
consistent between proximity FFPE and SPPICE biochemical
assays. c-MET phosphorylation was used to demonstrate that
HGF/c-MET detection can serve as a surrogate measure of c-MET
activation. In several glioma cells that exhibit activation of HGF/c-
MET signaling, we detected high levels of c-MET (pY1003)
phosphorylation that are likely modulated through a c-MET and
HGF autocrine loop. In contrast, our measurements of HGF, c-
MET, HGF/c-MET, and c-MET phosphorylation suggest that c-
MET activation in Ln229 cells is not the result of autocrine
signaling. At present, we do not understand the mechanism of
constitutive c-MET phosphorylation in this cell line, but it is
conceivable that signaling is mediated through an alternative co-
receptor or as yet unidentified c-MET activating mutations.
c-MET activation has recently been shown to play important
roles in HN carcinoma [2] via a paracrine mechanism in which
HGF is secreted by surrounding stromal cells [30]. Consistent with
this observation, we detected c-MET phosphorylation in NSCLC
and gastric tumors that also contained measurable levels of HGF/
c-MET complex. In NSCLC, Zucali et al [1] reported a significant
correlation between c-MET (pY1003) phosphorylation and
resistance to gefitinib treatment and rapid disease progression. A
similar association between gefitinib resistance and HGF induced
c-MET activation has also been reported for lung adenocarcino-
mas containing activating EGFR mutations [26]. Although, we
detected c-MET (pY1003) phosphorylation in human tumors, our
attempts to measure c-MET (pY1234/1235) and c-MET (pY1349)
phosphorylation were unsuccessful. It is possible that pY1003 c-
MET phosphorylation is inherently more stable than c-MET
(py1234/1235) phosphorylation. Alternatively, the kinetics of site-
specific phosphorylation may be different. A study of tyrosine
phosphorylation of c-MET in a renal carcinoma cell line suggested
that c-MET (pY1349) phosphorylation occurs 5 minutes after
HGF treatment and persists for 120 minutes while c-MET
(pY1234/1235) phosphorylation occurs 30 minutes after HGF
treatment and is subject to rapid turnover [31].
Strategies to identify relevant biomarkers in parallel with
development of targeted therapeutics is essential for the successful
selection of appropriate clinical trial subjects and eventual
treatment of potentially responsive patients. A number of
approaches for HGF/c-MET biomarker identification in a clinical
setting have been proposed including the measurement of plasma
HGF and shed c-MET [32]. Patients treated with a therapeutic
antibody against HGF (AMG102), exhibited increased plasma
HGF levels but no significant changes in shed c-MET [32]. In a
phase I of c-MET MetMab (Anti-MET therapeutic antibody), a
single patient that experienced a complete response exhibited a
diagnostic profile consistent with autocrine biology [33]. In
another study, c-MET phosphoryaltion was reduced in the post-
operative tumor biopsies of patients treated with a c-MET kinase
inhibitor (ARQ197) [34]. The VeraTag proximity assays de-
scribed here present a unique opportunity to provide quantitative
measurements of c-MET receptor activation that may contribute
to the development of antagonistic c-MET therapeutics.
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